Evidence map›Paper›PMID 35525393›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2023

Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study.

Edward L Barnes, Kristine H Allin, Aske T Iversen, Hans H Herfarth, Tine Jess

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06312683 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2024 to 2027Enrolled16ConditionsPouchitisArmsRifaximin 550 MG Oral Tablet [XIFAXAN]
NCT06864403 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2025 to 2027Enrolled25ConditionsPouchitis, Pouches, Ileoanal, Pouch, IlealArmsMirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Primary Prevention of Pouchitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Onset of pouchitis after colectomy for ulcerative colitis: reducing the risk.Expert review of gastroenterology & hepatology · 2025
    Article
  15. Observational
  16. Article
  17. Article
  18. Antibiotic Use in the 12 Months Prior to Ileal Pouch-Anal Anastomosis Increases the Risk for Pouchitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    Article
  19. Pouchitis: pathophysiology and management.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Edward L BarnesDivision of Gastroenterology and Hepatology; Multidisciplinary Center for Inflammatory Bowel Diseases; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: edward_barnes@med.unc.edu.
Kristine H AllinCenter for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Aske T IversenCenter for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Hans H HerfarthDivision of Gastroenterology and Hepatology; Multidisciplinary Center for Inflammatory Bowel Diseases; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Tine JessCenter for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Aalborg University Hospital · DKUniversity of North Carolina at Chapel Hill · USAalborg University · DK

Funding

Treatment Approaches and Outcomes in Pouch-related Disorders after Colectomy for Ulcerative ColitisK23DK127157 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARNES, EDWARD · 2021 to 2025
$1.0M
NIDDK NIH HHS K23 DK127157
6 · The paper itself

Abstract

BACKGROUND &

aimsCurrent knowledge regarding the epidemiology of pouchitis is based on highly selected, mostly single-center, patient cohorts. Our objective was to prospectively determine the population-based incidence of pouchitis in patients with ulcerative colitis in the first 2 years after ileal pouch-anal anastomosis and analyze time trends of the incidence of pouchitis.

methodsUsing national registries, we established a population-based cohort of all Danish patients undergoing proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis between 1996 and 2018. The primary outcome was the development of pouchitis within the first 2 years after surgery, evaluated by time period. We used Kaplan-Meier and Cox proportional hazard modeling to evaluate the time to development of pouchitis.

resultsOverall, 1664 patients underwent an ileal pouch-anal anastomosis. The cumulative incidence of pouchitis in the 2 years after ileal pouch-anal anastomosis increased throughout the study period, from 40% in the period from 1996 to 2000 (95% CI, 35%-46%) to 55% in the period from 2015 to 2018 (95% CI, 48%-63%). Patients undergoing surgery between 2015 and 2018 also showed an increased risk of pouchitis compared with the earliest study period (1996-2000) after adjusting for sex, age, and socioeconomic status (hazard ratio, 1.57; 95% CI, 1.20-2.05).

conclusionsThis population-based study showed a 15% absolute and 38% relative increase in the incidence of pouchitis among patients undergoing surgery between 1996 and 2018, with the greatest cumulative incidence of pouchitis shown in the most recent era (2015-2018). The striking increase in the incidence of pouchitis highlights the need for further research into causes and prevention of pouchitis.

Indexed as

Colitis, UlcerativeColonic PouchesPouchitisProctocolectomy, RestorativeCohort StudiesDenmarkHumansIncidenceAnti-Tumor Necrosis Factor αColectomyEpidemiologyIleal Pouch–Anal AnastomosisUlcerative Colitis

Identifiers

PMID35525393
PMCPMC9636065
OpenAlexW4229003610

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.